Economics, pharmacoeconomics and drug discovery for dementias

Drug Discovery Today

Volumn 7, Issue 15, 2002, Pages 785-787

  Fillit, Howard ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG INDUSTRY; EDITORIAL; HEALTH CARE COST; HOSPITAL COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MORBIDITY; PATHOGENESIS; QUALITY OF LIFE; RISK FACTOR; SENILITY; COST; DEMENTIA; ECONOMICS; UNITED STATES;

ALZHEIMER DISEASE; COSTS AND COST ANALYSIS; DEMENTIA; HUMAN; UNITED STATES; HUMANS;

EID: 0036668397     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02379-6     Document Type: Editorial

References (30)

1. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects
2. Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease
3. Current progress on new therapies for Alzheimer's disease
4. Epidemiology of dementia and Alzheimer's Disease
5. The US economic and social costs of Alzheimer's disease revisited
6. Estimated prevalence of Alzheimer's disease in the United States
7. Current concepts in mild cognitive impairment
8. Age associated memory impairment: Proposed diagnostic criteria and measures of clinical change - Report of a National Institute of Mental Health work group
9. The impact of donepezil on burden, health-related expenses and productivity of caregivers of patients with Alzheimer's disease
10. Cost of Alzheimer's disease and related dementia in managed Medicare
11. How much do persons with Alzheimer's disease cost Medicare?
12. The relative effect of Alzheimer's disease and related dementias, disability and comorbidities on cost of care for elderly persons
13. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare
14. Societal costs of vascular cognitive impairment in older adults
15. Costs of vascular dementia: A comparison with Alzheimer's disease]
16. Impact of the type and severity of dementia on hospitalization and survival of the elderly
17. The effect of dementia on acute care in a geriatric medical unit
18. A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
19. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
20. A 5-month, randomized, placebo-controlled trial of galantamine in AD
21. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
22. Potential savings in the cost of caring for Alzheimer's disease
23. An economic evaluation of donepezil in the treatment of Alzheimer's disease
24. Assessment of the health economics of Alzheimer's Disease (AHEAD): Galantamine treatment in Canada
25. The effect of donepezil therapy on health costs in a Medicare managed care plan
26. The progress study: Overall results on stroke and preliminary results on dementia
27. Perindopril protection against recurrent stroke study (progress): Methodology and overall findings
28. Aantihypertensive treatment prevents dementia: New evidence from the Syst-Eur trial
29. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease
30. Barriers to drug discovery for Alzheimer's disease